Literature DB >> 21349926

Subclinical lung disease, macrocytosis, and premature graying in kindreds with telomerase (TERT) mutations.

Alberto Diaz de Leon1, Jennifer T Cronkhite1, Cuneyt Yilmaz2, Cecelia Brewington3, Richard Wang4, Chao Xing1, Connie C W Hsia2, Christine Kim Garcia5.   

Abstract

BACKGROUND: Mutations in the human gene encoding the protein component of telomerase (TERT) are the most common genetic defect in patients with familial idiopathic pulmonary fibrosis (IPF). The subclinical phenotypes of asymptomatic members of these families have not been evaluated with respect to TERT mutation status or telomere length.
METHODS: We measured a variety of pulmonary, blood, skin, and bone parameters for 20 subjects with heterozygous TERT mutations (carriers) and 20 family members who had not inherited a TERT mutation (noncarriers) to identify the spectrum of phenotypes associated with mutations in this gene. The two groups were matched for sex, age, and cigarette smoking. Three TERT mutation carriers had IPF (IPF carriers). The rest of the carriers were apparently healthy (asymptomatic carriers) and were compared with the noncarriers.
RESULTS: Asymptomatic carriers exhibited significantly lower diffusing capacity of lung for carbon monoxide (Dlco), impaired recruitment of Dlco with exercise, radiographic signs of lung fibrosis, and increased fractional lung tissue volume quantified by high-resolution chest CT scan than noncarriers. RBC and platelet counts were significantly lower, and the mean corpuscular volume and mean corpuscular hemoglobin concentration were significantly higher in carriers than in noncarriers. Carriers reported significantly earlier graying of hair than noncarriers. TERT mutation status is more accurately predicted by short telomere lengths than any of these measured phenotypes.
CONCLUSIONS: TERT mutation carriers exhibit early preclinical signs of lung fibrosis, bone marrow dysfunction, and premature graying. These clinical features and short telomere lengths characterize patients with germline TERT mutations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21349926      PMCID: PMC3168855          DOI: 10.1378/chest.10-2865

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  34 in total

Review 1.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

2.  Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC.

Authors:  Tom Vulliamy; Anna Marrone; Richard Szydlo; Amanda Walne; Philip J Mason; Inderjeet Dokal
Journal:  Nat Genet       Date:  2004-04-18       Impact factor: 38.330

3.  Adult familial cryptogenic fibrosing alveolitis in the United Kingdom.

Authors:  R P Marshall; A Puddicombe; W O Cookson; G J Laurent
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

4.  Telomere length is inherited with resetting of the telomere set-point.

Authors:  Y Jeffrey Chiang; Rodrigo T Calado; Karen S Hathcock; Peter M Lansdorp; Neal S Young; Richard J Hodes
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

5.  Changes in the normal maximal expiratory flow-volume curve with growth and aging.

Authors:  R J Knudson; M D Lebowitz; C J Holberg; B Burrows
Journal:  Am Rev Respir Dis       Date:  1983-06

6.  High mean red cell volume: its incidence and significance in routine haematology.

Authors:  R J Davidson; P J Hamilton
Journal:  J Clin Pathol       Date:  1978-05       Impact factor: 3.411

7.  Very short telomeres in the peripheral blood of patients with X-linked and autosomal dyskeratosis congenita.

Authors:  T J Vulliamy; S W Knight; P J Mason; I Dokal
Journal:  Blood Cells Mol Dis       Date:  2001 Mar-Apr       Impact factor: 3.039

8.  Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred.

Authors:  Alan Q Thomas; Kirk Lane; John Phillips; Melissa Prince; Cheryl Markin; Marcy Speer; David A Schwartz; Radhika Gaddipati; Annis Marney; Joyce Johnson; Richard Roberts; Jonathan Haines; Mildred Stahlman; James E Loyd
Journal:  Am J Respir Crit Care Med       Date:  2002-05-01       Impact factor: 21.405

9.  Nitric oxide diffusing capacity and alveolar microvascular recruitment in sarcoidosis.

Authors:  Anagha R Phansalkar; Chad M Hanson; Ahmed R Shakir; Robert L Johnson; Connie C W Hsia
Journal:  Am J Respir Crit Care Med       Date:  2004-02-20       Impact factor: 21.405

10.  Familial idiopathic pulmonary fibrosis. Evidence of lung inflammation in unaffected family members.

Authors:  P B Bitterman; S I Rennard; B A Keogh; M D Wewers; S Adelberg; R G Crystal
Journal:  N Engl J Med       Date:  1986-05-22       Impact factor: 91.245

View more
  37 in total

1.  Short telomeres, telomeropathy, and subclinical extrapulmonary organ damage in patients with interstitial lung disease.

Authors:  Gautam George; Ivan O Rosas; Ye Cui; Caitlin McKane; Gary M Hunninghake; Phillip C Camp; Benjamin A Raby; Hilary J Goldberg; Souheil El-Chemaly
Journal:  Chest       Date:  2015-06       Impact factor: 9.410

Review 2.  Anemia of Central Origin.

Authors:  Kazusa Ishii; Neal S Young
Journal:  Semin Hematol       Date:  2015-07-09       Impact factor: 3.851

3.  Idiopathic pulmonary fibrosis a rare disease with severe bone fragility.

Authors:  Carla Caffarelli; Stefano Gonnelli; Maria Dea Tomai Pitinca; Valentina Francolini; Annalisa Fui; Elena Bargagli; Rosa Metella Refini; David Bennett; Ranuccio Nuti; Paola Rottoli
Journal:  Intern Emerg Med       Date:  2016-07-08       Impact factor: 3.397

Review 4.  Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis.

Authors:  Ana L Mora; Marta Bueno; Mauricio Rojas
Journal:  J Clin Invest       Date:  2017-02-01       Impact factor: 14.808

5.  Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.

Authors:  Ana L Mora; Mauricio Rojas; Annie Pardo; Moises Selman
Journal:  Nat Rev Drug Discov       Date:  2017-10-30       Impact factor: 84.694

Review 6.  Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Authors:  Ivan O Rosas; Paul F Dellaripa; David J Lederer; Dinesh Khanna; Lisa R Young; Fernando J Martinez
Journal:  Ann Am Thorac Soc       Date:  2014-04

7.  Running short on time: lung transplant evaluation for telomere-related pulmonary fibrosis.

Authors:  Christine Kim Garcia
Journal:  Chest       Date:  2015-06       Impact factor: 9.410

Review 8.  Telomeres in Interstitial Lung Disease: The Short and the Long of It.

Authors:  Andrew M Courtwright; Souheil El-Chemaly
Journal:  Ann Am Thorac Soc       Date:  2019-02

Review 9.  Subclinical interstitial lung disease: why you should care.

Authors:  Tracy J Doyle; Gary M Hunninghake; Ivan O Rosas
Journal:  Am J Respir Crit Care Med       Date:  2012-02-23       Impact factor: 21.405

Review 10.  Genetics and early detection in idiopathic pulmonary fibrosis.

Authors:  Rachel K Putman; Ivan O Rosas; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2014-04-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.